Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
262 SEK | -6.26% | +3.15% | +23.58% |
May. 03 | CellaVision AB Approves the Dividend, Payable on 13 May 2024 | CI |
Apr. 25 | Transcript : CellaVision AB, Q1 2024 Earnings Call, Apr 25, 2024 |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 36.46 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+23.58% | 593M | C+ | ||
-27.52% | 16.33B | A | ||
-40.04% | 2.96B | C+ | ||
+15.16% | 1.82B | - | ||
-6.86% | 1.55B | - | ||
+38.67% | 1.41B | B+ | ||
-15.36% | 976M | - | ||
-26.08% | 846M | - | C- | |
+3.53% | 811M | - | ||
-24.63% | 631M | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CEVI Stock
- Ratings CellaVision AB